Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world 2-year safety study of Ozurdex in Chinese patients with diabetic macular edema
CTR20243812Phase 4Active
- Sponsor
- AbbVie Inc.
- Start
- Nov 2024
- Modality
- Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 4 trial of ozurdex in diabetic macular edema (DME), sponsored by AbbVie Inc.. Started Nov 2024; status: active.
02
Drugs
ozurdex
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on CTR20243812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243812.